Suboptimal early inhibition of platelets by treatment with tirofiban and implications for coronary interventions.
Kabbani
Samer S
SS
University of Vermont, Burlington, Vermont 05446, USA.
Aggarwal
Atul
A
Terrien
Edward F
EF
DiBattiste
Peter M
PM
Sobel
Burton E
BE
Schneider
David J
DJ
D000077284:Abciximab; D015906:Angioplasty, Balloon, Coronary; D000911:Antibodies, Monoclonal / Q000009:adverse effects / Q000627:therapeutic use; D001780:Blood Coagulation Tests; D003327:Coronary Disease / Q000097:blood / Q000628:therapy*; D004359:Drug Therapy, Combination; D005340:Fibrinogen / Q000378:metabolism; D006493:Heparin / Q000008:administration & dosage; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000009:adverse effects / Q000627:therapeutic use; D010974:Platelet Aggregation / Q000187:drug effects*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D000077466:Tirofiban; D014443:Tyrosine / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D007140:Immunoglobulin Fab Fragments; D010975:Platelet Aggregation Inhibitors; D014443:Tyrosine; D005340:Fibrinogen; D006493:Heparin; D000077466:Tirofiban; D000077284:Abciximab